U.S. International Trade Commission Ends Antibody Drug Investigation
Estimated reading time: 1–2 minutes
The U.S. International Trade Commission (ITC) has chosen not to review an important decision. This decision involved ending an investigation related to antibody drug conjugates. Antibody drug conjugates are a type of medicine.
The ITC began this investigation on December 22, 2025. The investigation followed a complaint from AbbVie Inc. The company is from North Chicago, Illinois. They argued that certain companies were bringing antibody drugs into the U.S. by using their trade secrets. Trade secrets are special information that helps a company create its products. AbbVie said these actions might hurt U.S. industries.
The companies AbbVie raised concerns about included ProfoundBio in Seattle, Washington, and other international companies like Genmab in Denmark. The Office of Unfair Import Investigations also took part in the investigation.
On June 8, 2026, AbbVie asked to end the investigation. They did this by withdrawing their complaint. No one opposed this request. On June 15, 2026, the Office of Unfair Import Investigations supported this decision too.
By June 16, 2026, the Administrative Law Judge agreed to end the investigation. On July 1, 2026, the Commission agreed with this decision and officially closed the case.
The rules and laws that guided this conclusion come from section 337 of the Tariff Act of 1930.
This decision became official on July 2, 2026, as noted by Lisa Barton, Secretary to the Commission.
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
